Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-03-11T03:54:47.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:56:12.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2025-02-17T18:48:03.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T15:38:36.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.5%
    Check dated 2025-02-03T10:56:40.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-01-27T04:45:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.